Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis

Multiple Sclerosis and Related Disorders

Volumn 5, Issue , 2016, Pages 12-26

  Fiest, K M ^a   Walker, J R ^a   Bernstein, C N ^a   Graff, L A ^a   Zarychanski, R ^a   Abou Setta, A M ^a   Patten, S B ^b   Sareen, J ^a   Bolton, J M ^a   Marriott, J J ^a   Fisk, J D ^c   Singer, A ^a   Marrie, R A ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Anxiety; Depression; Meta analysis; Multiple sclerosis; Systematic review; Treatment

Indexed keywords

DESIPRAMINE; PAROXETINE; SERTRALINE;

ACCEPTANCE AND COMMITMENT THERAPY; ANXIETY DISORDER; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DRUG EFFICACY; HUMAN; MOTIVATIONAL INTERVIEWING; MULTIPLE SCLEROSIS; PATIENT COUNSELING; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; ADULT; AGED; ANXIETY DISORDERS; COMPLICATION; DEPRESSIVE DISORDER; META ANALYSIS; MIDDLE AGED; PSYCHOTHERAPY; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANXIETY DISORDERS; CLINICAL TRIALS AS TOPIC; COGNITIVE THERAPY; DEPRESSIVE DISORDER; HUMANS; MIDDLE AGED; MULTIPLE SCLEROSIS; PSYCHOTHERAPY; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84960472344     PISSN: 22110348     EISSN: 22110356     Source Type: Journal    
DOI: 10.1016/j.msard.2015.10.004     Document Type: Review

References (74)

1. Arroll, B., Macgillivray, S., Ogston, S., Reid, I., Sullivan, F., Williams, B., et al., 2005. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann. Fam. Med. 3 (5), 449-456.
2. Bandelow, B., Reitt, M., Rover, C., Michaelis, S., Gorlich, Y., Wedekind, D., 2015. Efficacy of treatments for anxiety disorders: a meta-analysis. Int. Clin. Psychopharmacol. 30 (4), 183-192.
3. Baron, K.G., Corden, M., Jin, L., Mohr, D.C., 2011. Impact of psychotherapy on insomnia symptoms in patients with depression and multiple sclerosis. J. Behav. Med. 34 (2), 92-101.
4. Beck, A.T., Steer, R.A., 1984. Internal consistencies of the original and revised Beck Depression Inventory. J. Clin. Psychol. 40 (6), 1365-1367.
5. Beck, A.T., Steer, R.A., Ball, R., Ranieri, W., 1996. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J. Pers. Assess. 67 (3), 588-597.
6. Beck, A.T., Ward, C.H., Mendelson, M., Mock, J., Erbaugh, J., 1961. An inventory for measuring depression. Arch. Gen. Psychiatry 4, 561-571.
7. Beckner, V., Vella, L., Howard, I., Mohr, D.C., 2007. Alliance in two telephone-administered treatments: relationship with depression and health outcomes. J. Consult. Clin. Psychol. 75 (3), 508-512.
8. Begg, C., Mazumdar, M., 1994. Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088-1101.
9. Beiske, A.G., Svensson, E., Sandanger, I., Czujko, B., Pedersen, E.D., Aarseth, J.H., et al., 2008. Depression and anxiety amongst multiple sclerosis patients. Eur. J. Neurol. 15 (3), 239-245.
10. Bombardier, C.H., Ehde, D.M., Gibbons, L.E., Wadhwani, R., Sullivan, M.D., Rosenberg, D.E., et al., 2013. Telephone-based physical activity counseling for major depression in people with multiple sclerosis. J. Consult. Clin. Psychol. 81 (1), 89-99.
11. Boutron, I., Guittet, L., Estellat, C., Moher, D., Hrobjartsson, A., Ravaud, P., 2007. Reporting methods of blinding in randomized trials assessing nonpharmacological treatments. PLOS Med. 4 (2), 0370-0380.
12. Brown, R.F., Valpiani, E.M., Tennant, C.C., Dunn, S.M., Sharrock, M., Hodgkinson, S., et al., 2009. Longitudinal assessment of anxiety, depression, and fatigue in people with multiple sclerosis. Psychol. Psychother. 82 (Part 1), 41-56.
13. Campbell, N., Boustani, M., Limbil, T., Ott, C., Fox, C., Maidment, I., et al., 2009. The cognitive impact of anticholinergics: a clinical review. Clin. Interv. Aging 4, 225-233.
14. Chandler, J., Churchill, R., Higgins, J., Lasserson, T., Tovey, D., 2013. Methodological standards for the conduct of new Cochrane Intervention Reviews, Version 2.3 from .
15. Cohen, J., 1988. Statistical Power Analysis for the Behavioral Sciences. Erlbaum, Hillsdale, NJ.
16. Cooper, C.L., Hind, D., Parry, G.D., Isaac, C.L., Dimairo, M., O'Cathain, A., et al., 2011. Computerised cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: external pilot trial. Trials 12, 259.
17. Cuijpers, P., Hollon, S., van Straten, A., Bockting, C., Berking, M., Andersson, G., 2013. Does cognitive behaviour therapy have an enduring effect that is superior to keeping patients on continuation pharmacotherapy? A meta-analysis. BMJ Open 3 (4).
18. Cuijpers, P., Li, J., Hofmann, S., Andersson, G., 2010. Self-reported versus clinician-rated symptoms of depression as outcome measures in psychotherapy research on depression: a meta-analysis. Clin. Psychol. Rev. 30, 768-778.
19. Cuijpers, P., Sijbrandij, M., Koole, S., Huibers, M., Berking, M., Andersson, G., 2014. Psychological treatment of generalized anxiety disorder: a meta-analysis. Clin. Psychol. Rev. 34 (2), 130-140.
20. Cuijpers, P., Sijbrandij, M., Koole, S.L., Andersson, G., Beekman, A.T., Reynolds III, C.F., 2013. The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons. World Psychiatry 12 (2), 137-148.
21. DiMatteo, M.R., Lepper, H.S., Croghan, T.W., 2000. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch. Intern. Med. 160 (14), 2101-2107.
22. Dubayova, T., Krokavcova, M., Nagyova, I., Rosenberger, J., Gdovinova, Z., Middel, B., et al., 2013. Type D, anxiety and depression in association with quality of life in patients with Parkinson's disease and patients with multiple sclerosis. Qual. Life Res. 22 (6), 1353-1360.
23. Egger, M., Smith, G., 1997. Bias in meta-analysis detected by simple, graphical test. Br. Med. J. 315, 629-634.
24. Ehde, D.M., Kraft, G.H., Chwastiak, L., Sullivan, M.D., Gibbons, L.E., Bombardier, C.H., et al., 2008. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen. Hosp. Psychiatry 30 (1), 40-48.
25. Feighner, J.P., Robins, E., Guze, S.B., Woodruff, R.A., Jr.Winokur, G., Munoz, R., 1972. Diagnostic criteria for use in psychiatric research. Arch. Gen. Psychiatry 26 (1), 57-63.
26. Fiest,K., Marrie, R.A., Abou-Setta, A., Zarychanski, R., 2015. Systematic review and metaanalysis of pharmacological and non-pharmacological interventions for depression and anxiety in persons with multiple sclerosis. CRD42015023773 from .
27. Fisk, J.D., Pontefract, A., Ritvo, P.G., Archibald, C.J., Murray, T.J., 1994. The impact of fatigue on patients with multiple sclerosis. Can. J. Neurol. Sci. 21 (1), 9-14.
28. Forman, A.C., Lincoln, N.B., 2010. Evaluation of an adjustment group for people with multiple sclerosis: a pilot randomized controlled trial. Clin. Rehabil. 24 (3), 211-221.
29. Fruehwald, S., Loeffler-Stastka, H., Eher, R., Saletu, B., Baumhackl, U., 2001. Depression and quality of life in multiple sclerosis. Acta Neurol. Scand. 104 (5), 257-261.
30. Gartlehner, G., Hansen, R.A., Morgan, L.C., Thaler, K., Lux, L., Van Noord, M., et al., 2011. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann. Intern. Med. 155 (11), 772-785.
31. Gray, S.L., Anderson, M.L., Dublin, S., Hanlon, J.T., Hubbard, R., Walker, R., et al., 2015. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern. Med. 175 (3), 401-407.
32. Guyatt, G., Oxman, A., Vist, G., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., et al., 2008. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336, 924.
33. Higgins, J.P., Altman, D.G., Gotzsche, P.C., Juni, P., Moher, D., Oxman, A.D., et al., 2011. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343, d5928.
34. Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., 2003. Measuring inconsistency in meta-analyses. BMJ 327 (7414), 557-560.
35. Humphreys, I., Drummond, A.E., Phillips, C., Lincoln, N.B., 2013. Cost-effectiveness of an adjustment group for people with multiple sclerosis and low mood: a randomized trial. Clin. Rehabil. 27 (11), 963-971.
36. Hunsley, J., Elliott, K., Therrien, Z., 2014. The efficacy and effectivenss of psychological treatment for mood, anxiety, and related disorders. Can. Psychol. 55 (3), 161-176.
37. Janssens, A.C., van Doorn, P.A., de Boer, J.B., Kalkers, N.F., van der Meche, F.G., Passchier, J., et al., 2003. Anxiety and depression influence the relation between disability status and quality of life in multiple sclerosis. Mult. Scler. 9 (4), 397-403.
38. Jones, K.H., Jones, P.A., Middleton, R.M., Ford, D.V., Tuite-Dalton, K., Lockhart-Jones, H., et al., 2014. Physical disability, anxiety and depression in people with MS: an internet-based survey via the UK MS Register. PLOS One 9 (8), e104604.
39. Koch, M.W., Glazenborg, A., Uyttenboogaart, M., Mostert, J., De Keyser, J., 2011. Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database Syst. Rev. (2), CD007295.
40. Korostil, M., Feinstein, A., 2007. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult. Scler. 13 (1), 67-72.
41. Kratz, A.L., Ehde, D.M., Bombardier, C.H., 2014. Affective mediators of a physical activity intervention for depression in multiple sclerosis. Rehabil. Psychol. 59 (1), 57-67.
42. Larcombe, N., Wilson, P., 1984. An evaluation of cognitive-behaviour therapy for depression in patients with multiple sclerosis. Br. J. Psychiatry 145, 366-371.
43. Lincoln, N.B., Yuill, F., Holmes, J., Drummond, A.E., Constantinescu, C.S., Armstrong, S., et al., 2011. Evaluation of an adjustment group for people with multiple sclerosis and low mood: a randomized controlled trial. Mult. Scler. 17 (10), 1250-1257.
44. Lynch, D., Laws, K.R., McKenna, P.J., 2010. Cognitive behavioural therapy for major psychiatric disorder: does it really work? A meta-analytical review of well-controlled trials. Psychol. Med. 40 (1), 9-24.
45. Marin, H., Menza, M.A., 2004. Specific treatment of residual fatigue in depressed patients. Psychiatry (Edgmont) 1 (2), 12-18.
46. Marrie, R.A., Fisk, J.D., Yu, B.N., Leung, S., Elliott, L., Caetano, P., et al., 2013. Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance. BMC Neurol. 13, 16.
47. Marrie, R.A., Reingold, S., Cohen, J., Stuve, O., Trojano, M., Sorensen, P.S., et al., 2015. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Mult. Scler. 21 (3), 305-317.
48. Minden, S.L., Feinstein, A., Kalb, R.C., Miller, D., Mohr, D.C., Patten, S.B., et al., 2014. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 82 (2), 174-181.
49. Minden, S.L., Frankel, D., Hadden, L., Perloffp, J., Srinath, K.P., Hoaglin, D.C., 2006. The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics. Mult. Scler. 12 (1), 24-38.
50. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 151 (4), 264-269, W64.
51. Mohr, D.C., Boudewyn, A.C., Goodkin, D.E., Bostrom, A., Epstein, L., 2001. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J. Consult. Clin. Psychol. 69 (6), 942-949.
52. Mohr, D.C., Classen, C., Barrera Jr., M., 2004. The relationship between social support, depression and treatment for depression in people with multiple sclerosis. Psychol. Med. 34 (3), 533-541.
53. Mohr, D.C., Cox, D., Merluzzi, N., 2005. Self-injection anxiety training: a treatment for patients unable to self-inject injectable medications. Mult. Scler. 11 (2), 182-185.
54. Mohr, D.C., Epstein, L., Luks, T.L., Goodkin, D., Cox, D., Goldberg, A., et al., 2003. Brain lesion volume and neuropsychological function predict efficacy of treatment for depression in multiple sclerosis. J. Consult. Clin. Psychol. 71 (6), 1017-1024.
55. Mohr, D.C., Genain, C., 2004. Social support as a buffer in the relationship between treatment for depression and T-cell production of interferon gamma in patients with multiple sclerosis. J. Psychosom. Res. 57 (2), 155-158.
56. Mohr, D.C., Goodkin, D.E., Islar, J., Hauser, S.L., Genain, C.P., 2001. Treatment of depression is associated with suppression of nonspecific and antigen-specific T (H)1 responses in multiple sclerosis. Arch. Neurol. 58 (7), 1081-1086.
57. Mohr, D.C., Hart, S.L., Goldberg, A., 2003. Effects of treatment for depression on fatigue in multiple sclerosis. Psychosom. Med. 65 (4), 542-547.
58. Mohr, D.C., Hart, S.L., Julian, L., Catledge, C., Honos-Webb, L., Vella, L., et al., 2005. Telephone-administered psychotherapy for depression. Arch. Gen. Psychiatry 62 (9), 1007-1014.
59. Mohr, D.C., Ho, J., Hart, T.L., Baron, K.G., Berendsen, M., Beckner, V., et al., 2014. Control condition design and implementation features in controlled trials: a meta-analysis of trials evaluating psychotherapy for depression. Transl. Behav. Med. 4 (4), 407-423.
60. Mohr, D.C., Likosky, W., Bertagnolli, A., Goodkin, D.E., Van Der Wende, J., Dwyer, P., et al., 2000. Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis. J. Consult. Clin. Psychol. 68 (2), 356-361.
61. Mohr, D.C., Spring, B., Freedland, K.E., Beckner, V., Arean, P., Hollon, S.D., et al., 2009. The selection and design of control conditions for randomized controlled trials of psychological interventions. Psychother. Psychosom. 78 (5), 275-284.
62. Nordin, L., Rorsman, I., 2012. Cognitive behavioural therapy in multiple sclerosis: a randomized controlled pilot study of acceptance and commitment therapy. J. Rehabil. Med. 44 (1), 87-90.
63. Politte, L.C., Huffman, J.C., Stern, T.A., 2008. Neuropsychiatric manifestations of multiple sclerosis. Prim. Care Companion J. Clin. Psychiatry 10 (4), 318-324.
64. R, 2014. R-Sock it to Me. The R Foundation for Statistical Computing.
65. Radloff, L., 1977. The CES-D Scale: a self-report depression scale for research in the general population. Appl. Psychol. Meas. 1 (3), 385-401.
66. Roshanaei-Moghaddam, B., Pauly, M.C., Atkins, D.C., Baldwin, S.A., Stein, M.B., Roy-Byrne, P., 2011. Relative effects of CBT and pharmacotherapy in depression versus anxiety: is medication somewhat better for depression, and CBT somewhat better for anxiety? Depress. Anxiety 28 (7), 560-567.
67. Schiffer, R.B., Wineman, N.M., 1990. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am. J. Psychiatry 147 (11), 1493-1497.
68. The Cochrane Collaboration, 2014. Review Manager (RevMan). The Nordic Cochrane Centre, Copenhagen.
69. Thomas, J., Brunton, J., Graziosi, S., 2010. EPPI-Reviwer 4: Software for Reserch Synthesis. EPPI-Centre Software. Social Science Research Unit, Institute of Education, London.
70. Turner, A.P., Williams, R.M., Sloan, A.P., Haselkorn, J.K., 2009. Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis. Rehabil. Psychol. 54 (1), 116-121.
71. van Straten, A., Geraedts, A., Verdonck-de Leeuw, I., Andersson, G., Cuijpers, P., 2010. Psychological treatment of depressive symptoms in patients with medical disorders: a meta-analysis. J. Psychosom. Res. 69 (1), 23-32.
72. Vitkova, M., Gdovinova, Z., Rosenberger, J., Szilasiova, J., Nagyova, I., Mikula, P., et al., 2014. Factors associated with poor sleep quality in patients with multiple sclerosis differ by disease duration. Disabil. Health J. 7 (4), 466-471.
73. Watts, S., Turnell, A., Kladnitski, N., Newby, J., Andrews, G., 2015. Treatment-asusual (TAU) is anything but usual: A meta-analysis of CBT versus TAU for anxiety and depression. J. Affect. Disord. 175, 152-167.
74. Zigmond, A.S., Snaith, R.P., 1983. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 67 (6), 361-370.